feed,title,long_url,short_url
Benzinga,Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial,https://benzinga.com/general/biotech/21/07/22035818/mesoblast-shares-90-day-survival-outcomes-after-remestemcel-l-from-covid-19-ards-trial,https://j.mp/3kDYKDT
